OMEICOS Therapeutics GmbH - Cardiovascular

Cardiovascular disease

The mission of OMEICOS Therapeutics is to develop a safer, patient-friendly drug for long-term heart rhythm control, that not only improves the quality of life of Atrial fibrillation patients by preventing atrial fibrillation episodes but also provides a curative effect to the diseased heart

 

Atrial fibrillation

Normally, the heart contracts and relaxes in a regular fashion. Atrial fibrillation, or AF for short, is the most common cardiac arrhythmia characterized by an irregular and often rapid heartbeat. This can lead to severe instability of blood circulation causing blood clots, stroke, heart failure and other cardiac complications. 

In daily life, patients with AF suffer from shortness of breath and impaired exercise capacity including episodes of palpitations that causes nervous reactions like sweating, dizziness and feelings of anxiety. Taken together, these symptoms significantly reduce the quality of life of AF patients such as doubling their risk of death, increasing their risk of stroke almost five-fold and raising their overall risk of heart failure.

Existing anti-arrhythmic drugs in the market only have a limited effect of suppressing AF symptoms and are often associated with the risk of serious side effects.

In contrast to all other drugs currently on the market that act almost exclusively via direct inhibition of ion channels, our molecules activate an endogenous cardio-protective signalling pathway. In preclinical trials, our compounds could not only stabilize the heart rhythm, but also provide curative effects to the diseased heart by preventing the remodeling of its electrical and structural properties.

Market

In 2013, approximately 13 million diagnosed prevalent cases of AF were reported in the G7 countries in 2013. Hereof, 4.7 million patients in the United States, 6.5 million patients in the European countries and 1.7 million patients in Japan were living with AF. 

The prevalence of AF increases with age. People older than 40 years have about a 25% chance of developing AF in their lifetime.

Based on these statistics, the market for AF drugs is expected to increase from USD 6.1bn in 2013 to almost USD 9bn by 2023. Within this market, the share for anti-arrhythmic drugs has been forecasted at USD 2bn in 2023.

Limited options for drug therapy as well as increasing numbers of patients suffering from AF result in a very high unmet medical need for a safe and efficient new anti-arrhythmic drug.